The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Self-citationWagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171 · cited 3×
“therapy, and although a survival advantage over single-agent 5-FU or FAMTX or docetaxel cisplatin/5-fluorouracil (DCF) was not shown in phase III trials [6, 8, 9], it was recommended as an acceptable combination for those patients for whom three-drug regimens are considered unacceptable [4].”
BackgroundWebb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 870
Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma
D'Angelica, M., Gonen, M., Brennan, M. F., Turnbull, A. D., Bains, M., & Karpeh, M. S. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000143245.28656.15 · Cited by 627
Vanhoefer, U., Rougier, P., Wilke, H., Ducreux, M. P., Lacave, A. J., Van Cutsem, E., Planker, M., Santos, J. G. D., Piedbois, P., Paillot, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2648 · Cited by 531
Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Oates, J., & Ross, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.154 · Cited by 524
Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.105 · Cited by 475
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
Pinto, C., Di Fabio, F., Siena, S., Cascinu, S., Rojas Llimpe, F. L., Ceccarelli, C., Mutri, V., Giannetta, L., Giaquinta, S., Funaioli, C., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl459 · Cited by 283
Waters, J. S., Norman, A., Cunningham, D., Scarffe, J. H., Webb, A., Harper, P., Joffe, J. K., Mackean, M., Mansi, J., Leahy, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690350 · Cited by 275
Bouché, O., Raoul, J. L., Bonnetain, F., Giovannini, M., Etienne, P. L., Lledo, G., Arsène, D., Paitel, J. F., Guérin-Meyer, V., Mitry, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.140 · Cited by 274
Ajani, J. A., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4968 · Cited by 250
Roth, A. D., Fazio, N., Stupp, R., Falk, S., Bernhard, J., Saletti, P., Köberle, D., Borner, M. M., Rufibach, K., Maibach, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0135 · Cited by 243
Design and analysis of non‐inferiority mortality trials in oncology
Rothmann, M., Li, N., Chen, G., Chi, G. Y. H., Temple, R., & Tsou, H. (2003) · Statistics in Medicine · doi:10.1002/sim.1400 · Cited by 243
Points to consider on switching between superiority and non‐inferiority
Committee for Proprietary Medicinal Products (CPMP) (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01397-3.x · Cited by 236
Ajani, J. A., Baker, J., Pisters, P. W. T., Ho, L., Mansfield, P. F., Feig, B. W., & Charnsangavej, C. (2002) · Cancer · doi:10.1002/cncr.10279 · Cited by 160
Pozzo, C., Barone, C., Szántó, J., Pádi, É., Peschel, C., Bükki, J., Горбунова, В. А., Valvere, V., Załuski, J., Biakhov, M. Y., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh473 · Cited by 158
Self-citationA useful testing strategy in phase iii trials: combined test of superiority and test of equivalence
Morikawa, T., & Yoshida, M. (1995) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409508835115 · Cited by 137
Incidence and mortality from stomach cancer in Japan, Slovenia and the USA
Lambert, R., Guilloux, A., Oshima, A., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.10150 · Cited by 123
Shah, M. A., Ilson, D. H., & Kelsen, D. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.81.908 · Cited by 119
Moehler, M. H., Eimermacher, A., Siebler, J., Höhler, T., Wein, A., Menges, M., Flieger, D., Junginger, T., Geer, T., Gracien, E., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602649 · Cited by 97
Köhne, C.-H., Catane, R., Klein, B., Ducreux, M. P., Thuss-Patience, P. C., Niederle, N., Gips, M., Preusser, P., Knuth, A., Clemens, M., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601226 · Cited by 86
Self-citationLutz, M. P., Wilke, H., Wagener, D. J. T., Vanhoefer, U. J., Jeziorski, K., Hegewisch‐Becker, S., Balleisen, L., Joosens, E., Jansen, R. L., Debois, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1666 · Cited by 69
Enzinger, P. C., Kulke, M. H., Clark, J. W., Ryan, D. P., Kim, H. T., Earle, C. C., Vincitore, M., Michelini, A. L., Mayer, R. J., & Fuchs, C. S. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-3038-2 · Cited by 66
Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy.
Osoba, D., Murray, N., Gelmon, K. E., et al. (1994) · PubMed · Cited by 42
Epirubicin, Cisplatin, and Fluorouracil in Gastric and Esophageal Cancer: A Step Ahead?
Ilson, D. H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.8.1962 · Cited by 12
Moehler, M. H., Trarbach, T., Seufferlein, T. T. W., et al. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71021-2 · Cited by 4
Cited by
Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30354-3 · Cited by 1,793
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Fanta, P., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0008 · Cited by 1,684
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw350 · Cited by 1,555
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., & Smyth, E. C. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.004 · Cited by 1,503
Metadata
- Authors
- Dank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., Wenczl, M., Goker, E., Cisar, L., Wang, K., & Bugat, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 19
- Issue
- 8
- Pages
- 1450-1457
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2104709039
- Cited by
- 343
- References
- 30
- FWCI
- 25.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.